Navigation Links
CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials

COPENHAGEN, Denmark; SEATTLE; STRASBOURG, France; and SAN FRANCISCO, Dec. 17, 2013 /PRNewswire/ -- CMC Biologics and OncoSynergy announced today that the two companies entered into an agreement for cell-line development, process development, analytical development and manufacturing of non-GMP material to enable early toxicology testing and cGMP material for IND enabling toxicology studies and Phase I clinical trials. This work will advance OncoSynergy's OS2966 monoclonal antibody program based on its "Targeted Synergy" approach - a transformative strategy allowing broad inhibition of multiple fundamental cancer growth mechanisms with a single drug.



"We look forward to helping advance OncoSynergy's OS2966 drug platform targeting cancers resistant to currently available therapies," said Gustavo Mahler, Global Chief Operations Officer of CMC Biologics. "This contract highlights CMC Biologics' proven and trusted platform for monoclonal antibody development and manufacturing." 

The project will be executed by CMC Biologics at its Copenhagen development and manufacturing facility. OncoSynergy EU SAS in France will lead the project.

"We are impressed with CMC Biologics' experience and technical competency in biopharmaceutical development and cGMP manufacturing," said OncoSynergy Co-Founder and CEO, Shawn Carbonell, MD, PhD. "Choosing a partner who can provide a complete solution - from expression of the sequence of interest, to providing material suitable for clinical trials - was a critical decision as we advance our lead candidate. They have also shown flexibility to accommodate our unique program needs as a virtual startup company."

About OncoSynergy
OncoSynergy is a privately-held biotechnology company based in San Francisco, California and Strasbourg, France. The mission of OncoSynergy is to radically improve health outcomes for patients by addressing unmet needs in oncology and neurofibromatosis. Its therapies are drug platforms featuring "Targeted Synergy" - multiple mechanisms of action for maximal effectiveness. OncoSynergy's lead drug, OS2966, blocks a critical path for growth and therapy resistance in cancer and is under development for the treatment of glioblastoma. OncoSynergy's therapeutic platforms have been developed at several world-class institutions including by its founders at UCSF and by Martin Karplus of Harvard University - a 2013 Nobel Prize in Chemistryawardee. To learn more, visit

About CMC Biologics 
CMC Biologics is a dedicated contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes. To learn more, visit

Media Contacts:
Stacie D. Byars
CMC Biologics Global Marketing
+1 (206) 660-2588

Robert Dunkle
OncoSynergy, Inc.
+1 (415) 978-2153

SOURCE CMC Biologics; OncoSynergy
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Crescendo Biologics Raises £17.5M ($28M) in Series A Financing
2. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
3. Synthetic Biologics Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th
4. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
5. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
6. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
7. Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety
8. Bone Biologics to Webcast, Live, at on September 12th
9. Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
10. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
11. Oncobiologics and inVentiv Health Form Strategic Partnership around Biosimilars
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... , June 23, 2016 ... "Surgical Procedure Volumes: Global Analysis (United States, China, ... Canada)" report to their offering. ... essential tool for healthcare business planners, provides surgical procedure ... at surgery trends with an in-depth analysis of growth ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):